




NIPT

Non-invasive Prenatal Test to deliver assurance to expectant parents

What is MedGenome NIPT?

MedGenome Non-invasive Prenatal Testing (NIPT) uses advanced bio-informatics technology to evaluate fetal DNA (of placental origin) in maternal blood to identify genetic variations that can lead to disorders.



Powered by iFACT

(Individualized Fetal Aneuploidy Confidence Test)

Non - Invasive genetic test for Precise Management

 \checkmark

Assay uses a dynamic threshold metric known as iFACT to make chromosomal aneuploidy calls.

 \checkmark

Indicates whether the system has generated sufficient sequencing coverage, given the fetal fraction estimate for each sample.





Ensures high accuracy of the result.

MedGenome NIPT: Screens for the Most Common Aneuploidies and rare autosomal aneuplodies

Common Aneuploidies		
Trisomy 21		
Trisomy 18		
Trisomy 13		
Sex Chromosome Aneuploidies		
XO (Turner Syndrome)		
XXX (Trisomy X)		
XXY (Klinefelter syndrome)		
XYY (Jacob's syndrome)		
Rare Autosomal Aneuplodies		

Methodology



Cell-free DNA (cfDNA) from both the fetus and the mother is found in the maternal blood.



Next Generation Sequencing (NGS) can detect and measure aneuploidy within this mixed sample.



Quantitative differences in cfDNA in maternal blood can be used to distinguish fetuses affected with abnormalities such as trisomy 21, trisomy 18, trisomy 13 from those that are unaffected. MedGenome NIPT is based on Illumina VeriSeq version 2 Solution to deliver Whole Genome Sequencing (WGS) approach to Non Invasive Prenatal Test (NIPT)



Provides a comprehensive view of the chromosomes.



Offers an enhanced counting technique along with cutting edge algorithms to determine the risk of aneuploidies based on a ratio between chromosomes of interest to multiple reference chromosome.

Key Highlights of MedGenome NIPT

1. Comprehensive view of fetal genome




2. Test Performance

- Sensitivity and specificity of >99.9% for trisomy 21, 18, 13
- >99% call rate

Common Aneuploidies	Sensitivity	Specificity
Trisomy 21	>99.9%	>99.9%
Trisomy 18	>99.9%	>99.9%
Trisomy 13	>99.9%	>99.9%
Any Anomaly	95.5%	99.34%

Accuracy of VeriSeq[™] V2 for detecting sex chromosomes aneuploidies.

3. Low Test Failure Result




4. Fastest Test Result



MedGenome NIPT offers a fast three step automated workflow for NIPT.


Turn around time is less than or equal to 7 working days.


5. Extensive Validation on Indian Samples




Concordance of MedGenome NIPT for detecting sex chromosomes aneuploidies in MedGenome internal clinical validation.

Why MedGenome NIPT is Superior?







Precision in Reproductive Genetic solutions

